ECOR Archives - BioTuesdays

Executive Moves

Dr. Thomas J. Errico elected electroCore’s chairman of the board; Peter Cuneo retires

electroCore (NASDAQ: ECOR) has announced the election of Thomas J. Errico, MD, as chairman of the board and the departure of Peter Cuneo from its board of directors (BOD). According to electroCore, Mr. Cuneo will...

September 5, 2025

Developments

electroCore acquires NeuroMetrix gaining access to Quell platform

electroCore (NASDAQ:ECOR) announced it has completed the merger with NeuroMetrix (NASDAQ:NURO), expanding its portfolio to include Quell Fibromyalgia Solution, strengthening its commercial reach, and positioning the...

May 2, 2025

Developments

electroCore reports positive topline results from migraine prevention study

electroCore (NASDAQ:ECOR) reported positive topline results from its PREMIUM II study evaluating gammaCore, a non-invasive vagus nerve stimulation (nVNS) device, for the prevention of migraines. The study was designed...

December 8, 2020

Markets

Brookline starts electroCore at buy; PT $5

Brookline Capital Markets launched coverage of electroCore (NASDAQ:ECOR) with a “buy” rating and price target of $5. The stock closed at $1.57 on Oct. 22. electroCore is a bioelectronic medicine company whose lead...

October 23, 2020

Markets

HCW ups electroCore PT to $2.50 from $1.50

H.C. Wainwright raised its price target for electroCore (NASDAQ:ECOR) to $2.50 from $1.50, citing the FDA’s emergency use authorization of gammaCore, the company’s lead product, to treat COVID-19 patients. The stock...

July 15, 2020

Developments

FDA authorizes emergency use of electroCore’s vagus nerve stimulation in COVID-19 patients

The FDA has issued an emergency use authorization for electroCore’s (NASDAQ:ECOR) gammaCore Sapphire CV non-invasive vagus nerve stimulation (nVNS) to treat adult patients with known or suspected COVID-19. The FDA has...

July 13, 2020

Markets

HCW starts electroCore at buy; PT $2

H.C. Wainwright initiated coverage of electroCore (NASDAQ:ECOR) with a “buy” rating and $2 price target. The stock closed at 65 cents on March 9. electroCore is commercializing its lead product, gammaCore, the only FDA...

March 10, 2020

Executive Moves

electroCore names Daniel Goldberger as CEO

Daniel Goldberger electroCore (NASDAQ:ECOR) has appointed Daniel Goldberger as CEO, effective Oct. 1. Mr. Goldberger has more than 35 years of experience in the biotechnology and medical technology industries; with...

September 30, 2019

Feature

electroCore focused on U.S. launch of gammaCore for acute treatment of episodic cluster headaches and migraines

By Len Zehr With FDA approval in hand for its gammaCore Sapphire therapy for the acute treatment of episodic cluster headaches and migraines, electroCore (NASDAQ:ECOR) is now focused on commercialization and...

September 25, 2018

Tag - ECOR

Dr. Thomas J. Errico elected electroCore’s chairman of the board; Peter Cuneo retires

electroCore acquires NeuroMetrix gaining access to Quell platform

electroCore reports positive topline results from migraine prevention study

Brookline starts electroCore at buy; PT $5

HCW ups electroCore PT to $2.50 from $1.50

FDA authorizes emergency use of electroCore’s vagus nerve stimulation in COVID-19 patients

HCW starts electroCore at buy; PT $2

electroCore names Daniel Goldberger as CEO

electroCore focused on U.S. launch of gammaCore for acute treatment of episodic cluster headaches and migraines

Subscribe